Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Another BACE inhibitor fails in phase III trials
  2. May’s top news stories
  3. US biosimilar setbacks highlight difficulty of cost-effective development
  4. PD-L1 biomarker makes a comeback in bladder cancer
  5. POINT trial may increase clopidogrel use in secondary ischemic stroke prevention

Latest Content

Another BACE inhibitor fails in phase III trials

On June 12, AstraZeneca and Eli Lilly terminated their two Phase III clinical trials of oral amyloid targeting β-secretase (BACE) inhibitor lanabecestat in Alzheimer’s disease (AD). The partners made the decision to terminate AMARANTH (NCT02245737) and the DAYBREAK-ALZ (NCT02783573) trials after an independent data monitoring committee concluded they were unlikely to meet primary endpoints based on interim analysis. The related AMARANTH extension trial (NCT02972658) will also be discontinued. This termination is preceded by recent failures of BACE inhibitors in late stage clinical development for the treatment of AD.

ImmunXperts Company Video

ImmunXperts is a young company with rich history. It has a flexible development team, and focuses on quality and innovation.

May’s top news stories

Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.

US biosimilar setbacks highlight difficulty of cost-effective development

Complete response letters (CRLs) were issued by the FDA recently for two biosimilar versions of Roche’s Rituxan—first to Celltrion and Teva on April 9 for Truxima and then to the Sandoz division of Novartis on May 3 for Rixathon, over two months ahead of its Prescription Drug User Fee Act (PDUFA) date, effectively stalling rituximab biosimilar development in the US.

PD-L1 biomarker makes a comeback in bladder cancer

PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of PD-1/L1 inhibitors in the disease have reported clinical benefit even in patients who have low or undetectable levels of the biomarker.

Phase II most common among immuno-oncology trials, 2008-2017

GlobalData has reviewed the phase of global clinical trials in the immuno-oncology (IO) space that were initiated between 2008 and 2017. For the purposes of this analysis, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top